Detection of abnormal peripheral blood mononuclear cell cytokine networks in human IgA nephropathy. Dysregulated cytokine expression has been implicated in the pathogeneis of IgA nephropathy, but the mechanisms and selectivity of this response are poorly understood. In this study we have examined the expression of a range of immunoregulatory cytokine mRNAs by peripheral blood mononuclear cells (PBMNCs) from 45 patients with igA nephropathy stratified empirically according to urinary red cell excretion: 10 in remission, and 35 with active disease (21 mild, 14 moderate), and 17 normal, and 15 disease, controls. We used a semi-quantitative polymerasc chain reaction (PCR) technique. None of the patients had experienced recent episodes of macroscopic hematuria. Simultaneous analysis of monocyte class 11 antigen (DR) expression was also performed by two-color immunoflow cytometry. TGF-/3l mRNA was detected in 68% (24 of 35) of patients with active, and 70% (7 of 10) inactive IgA nephropathy, but in only 18% (3 of 17) normal (P < 0.005), and 27% (4 of 15) disease controls. IL-6 transcripts were identified in 37% (13 of 35) of patients with active
Isolated studies have demonstrated that cultured peripheral blood MNCs from patients with IgA nephropathy have the capacity to secrete high levels of the cytokines interleukin (IL)-2 [10, 11] , y-interferon (IFN) [11] and IL-6 [12, 13] , which may have a direct impact on lymphocyte function and immunoglobulin secretion [14] . Mononuclear cells (MNC) have a central role in host response to infecting pathogenetic organisms, and there is also evidence of abnormal renal trafficking of MNC in these patients, with the accumulation of infiltrating mononuclear phagocytes during active disease [15, 16] . While the deposition of nephritogenic antibodies may be involved in one limb of this process [6, 7] , cellular depletion studies indicate that these cells may be important mediators of glomerular injury [17] [18] [19] . This process is likely to involve the secretion of a range of cytokines by activated infiltrating MNCs, as these are known to exert paracrine effects on both endothelial [201, and mesangial cell types [21] . Furthermore, in vitro studies demonstrate that endotoxin stimulated monocytes secrete soluble factors which induce marked proliferative [22] , and secretory [23] responses in cultured mesangial cell monolayers. In addition, mesangial expression of cytokines such as tumor necrosis factor (TNF)-a, IL-6, and transforming growth factor (TGF)-f3, which are also secreted in high concentrations by activated monocytes, are autoinduced [21, 24, 25] . Evidence for this process in vivocomes from studies using anti-cytokine blocking antibodies [26] [27] [28] , or with the exogenous administration of recombinant cytokines [29, 30] , in which these manipulations have significantly modulated glomerular injury in experimental nephropathies. In human disease we identified enhanced tissue expression of IL-6, and other mRNAs [31] , and IL-6 protein [32] in the glomeruli and renal interstitium of patients with IgA nephropathy, with increased urinary IL-6 excretion associated with disease activity [33, 34] .
The mechanism and balance of MNC cytokine expression in
IgA nephropathy is, however, poorly understood. Isolated study of T cell or monocyte derived factors fails to account for the complex interactive network of secreted cytokines which are operative in vivo, and it is unclear whether there is a generalized or selective dysregulation of cytokine expression in this condition. Furthermore, while the secretion of cytokines IL-2, y-IFN and IL-6 in cell culture supernatants may reflect endogenous activation of circulating MNCs in vivo, it may equally represent an ex vivo artifact associated with cell manipulation in culture [35, 36] . The aim of this study was, therefore, to determine whether there is endogenous dysregulation of cytokine expression and cellular activation in MNCs from patients with IgA nephropathy in the context of a network of lymphocyte and monocyte derived factors.
Methods

Patients and controls
We studied 45 patients with primary IgA nephropathy, 31 male, 14 female, age [mean (SD)] 42 (13.8) years. These were empirically stratified according to urinary red cell excretion: 10 in remission (<8 RBCs/mm3 urine), 35 with active disease, comprising 21 mild (8 to 100 RBCsImm3 urine) and 14 with moderate disease activity (>100 RBCs/mm3 urine). There were also 15 disease controls, 7 male, 9 female, age 41.9(13.8) years, 7 with non-IgA (1gM) mesangial proliferative GN (MPGN), and 8 with chronic renal failure (CRF) of non-immune' etiology, 5 due to chronic pyelonephritis, and 3 with hypertensive nephrosclerosis. In addition there were 17 healthy volunteers, 11 male, 6 female, age 41.9 (13.8) years, serving as normal controls. Serum creatinine levels and 24-hour urinary protein excretion were determined simultaneously (Fig. 1) . All patients had stable renal function (<15% increase in serum creatinine over 12 months), negative serology for systemic lupus erythematosis, and had no clinical evidence of systemic or hepatic disease. Among the patients with active IgA nephropathy, 22 had the clinical picture of persistent or intermittent microscopic hematuria, and 13 a pattern of relapsing macroscopic urinary blood loss. None had experienced recent episodes of macroscopic hematuria at the time of study (2 months), and none of the patients or controls had received immunosuppressive therapy or steroids prior to the study.
Sample preparation and cell culture
Peripheral blood MNCs were isolated from heparinized venous blood using a standard ficoll/metrizoate gradient (Lymphoprep, Nycomed Pharma, Norway), and the cell pellet washed in PBS for subsequent analysis. As a positive control, 10 ml of fresh, anticoagulated peripheral venous blood were incubated in 25 ml screw cap siliconized glass bottles ('Repelcote', BDH, UK), with 1 j.tg/ml of lipopolysaccharide (LPS) (E. coli, Olll:B4; Sigma Chemicals, UK), sealed after exposure to 5% CO2 humidified incubator for 15 minutes, and placed on a blood roller at 50 rpm at 37°C for two to six hours prior to MNC separation. Analysis of mononuclear cell RNA RNA isolation and reverse transcription (RT). Total MNC RNA was isolated using a modified guanidine hydrochloride! phenol extraction procedure [37] . Initially, cellular viability was determined by Trypan blue exclusion (>95%), and the MNC pellet resuspended in 5 ml of lysis buffer (6 M guanidine hydrochloride and 0.2 M Na acetate, pH 5.5). Following this, 2.5 ml of 100% ethanol were added and the sample stored at -20°C overnight. After centrifugation at 4°C for 30 minutes at 10 K rpm, the supernatant was removed, the RNAlprotein pellet resuspended in urea buffer (6 M urea, 0.35 M Na chloride, 50 mM Tris pH 7.5, 1 mi EDTA and 0.2% SDS), and the protein mixture extracted with water saturated phenol/chloroform (1:1). Total RNA was then alchohol precipitated; washed, resuspended in diethylpyrocarbonate (DEPC) treated water, and stored at -20°C for subsequent analysis. The concentration of RNA was initially estimated by spectrophotometry (OD2). Denaturing gel electrophoresis was subsequently performed to confirm RNA integrity, using a known concentration of RNA standard, to provide an accurate estimate of sample concentra- cDNA synthesis was performed using a single stranded cDNA synthesis kit ('Superscipt pre-amp': Gibco, BRL) according to the manufacturer's instructions. Briefly, 1 g of total RNA template was intially heated to 90°C for five minutes to reduce secondary structure, quick-chilled on ice and then incubated with 0.5 g of oligo dT primer at 70°C for 10 minutes. After chilling on ice, this was incubated for 10 minutes at room temperature followed by 50 Multiple cytokine mRNA phenotyping using the polymerase chain reaction technique. It is possible to analyze multiple cytokine mRNAs from a single cDNA preparation using the PCR technique, so-called mRNA phenotyping [38] . For this, 1 sl of the cDNA product was mixed with 1 unit of gelatine-free TAC polymerase and reaction buffer containing 50 mri KCI, 10 mM Tris HCI, pH 9.0, 0.1% Triton x 100 (Promega, UK). In addition, 200 M lithium dNTPs (Boehringer Mannheim Biochemica), 20 sM of each primer pair (see below), and MgCI2
were added, the latter titrated independently to determine the optimal concentration for each amplification product, ranging from 2 to 10 LM. The final reaction made up to 50 .d with UV irradiated DEPC treated water, and overlaid with mineral oil (Sigma Chemicals). A master mix of PCR components was made up for each set of reactions prior to addition of the cDNA templates, to reduce variations in reaction components. To reduce contamination, RT-PCR preparation was performed in a designated part of the laboratory, and all stock solutions, pipettes and tips regularly irradiated with UV light to break down contaminant DNA structures. Synthetic 25'mer oligonucleotide primers (a gift from ICI Pharmaceuticals, UK) were designed from previously published human sequences using the "Genebank" database (Table 1) . These were oriented on separate exons so that the PCR product from cDNA amplification could be distinguished from contaminating genomic DNA products according to their size. As a positive internal control of RT-PCR efficiency, primers were derived for the constitutively expressed "housekeeper" gene, glyceraldehyde 3-phosphate dehydrogenase (GAPDH). The reactions were performed using a waterbath thermal cycler (Grant Ampligene) with samples initially heated to 94°C for two minutes to reduce secondary structure, followed by one minute at the optimal annealing temperature for each set of primers [(Interleukin (IL)-la, IL1f3, IL-2 and IL-4: 55°C; tumor necrosis factor (TNF)-a, IL-6, y-interferon (IFN) and GAPDH: 60°C], one minute at 72°C and 30 seconds at 94°C over 25 to 35 cycles. Ten microliters of the PCR product were then analyzed by electrophoresis on a 1% agarose gel, and visualized by ethidium bromide staining under UV light.
Conditions for a semi-quantitative RT-PCR were determined by establishing the minimal number of amplification cycles (25 to 35) for each set of primers which could be used to distinguish LPS stimulated MNC mRNAs from unstimulated controls (Fig.  2 ). The range of cytokine mRNA products was detectable from LPS stimulated but not from unstimulated MNCs at a given cycle interval, with selective appearance of certain mRNAs in some patients with IgA nephropathy (Fig. 3) . Accordingly, results were expressed as the percentage of samples in a particular group of patients or controls with detectable mRNA species, and provided an estimate of mRNA abundance relative to the normal control group.
Two color immunofluorescence flow cytometry. Freshly isolated MNCs were washed in ice-cold PBS with 0.2% sodium Azide (PBS/A), and blocked with 20% normal human serum on ice for 30 minutes. Subsequent incubations were performed using 5 -i0 cells in 100 p1 final volume, on ice in two stages, each for 30 minutes with 20% human serum in PBS/A. Phycoerythrin (PE) conjugated mouse anti-human CD 14 monoclonal antibody (Dako Ltd, UK), an IgG2a isotype, was used as a specific monocyte marker, and a mouse anti-human DR monoclonal (Serotec, UK), an 1gW isotype recognizing a nonpolymorphic epitope, to analyse class II antigen expression. In addition, an irrelevant IgGi isotype was used as a negative control (Serotec), and antibodies titrated to an optimal working concentration. After washing in PBS/A, an isotype-specific fluorescein isothiocyanate (FITC) conjugated goat anti-mouse IgGi secondary antibody demonstrating low cross reactivity with the IgG2a isotype anti-CD 14 monoclonal antibody (Nordic Immunologicals, UK) was used at the recommended working concentration. Mter washing in PBS/A, samples were resuspended in 300 .tl of PBS/A and stored in the dark at 4°C prior to analysis. Flow cytometric analysis was performed on a FACScan flow cytometer using FAScan Research softwear (Beckton Dickinson). During acquisition, data were collected on 2,500 events with a live gate set on CD 14 PE positive (monocyte) ILi U cells. FITC fluorescence signals were represented graphically on a logarithmic scale, and for data analysis as the percentage DR positive cells (Fig. 4) . MNC composition for RNA analysis was determined by setting markers on CD 14 PE fluorescence iLl I
histograms to determine the percentage of monocytes in a given sample.
Statistical analysis Statistical analysis was performed using Stat-View SE softwear (Apple Computer mc). Complete mRNA data were available for all samples, but for technical reasons, a small number of immuno-flowcytometric studies was unsuccessful, and therefore excluded from the analysis. Multiple group testing was performed by one way ANOVA, and where the likelihood of a significant difference between groups was >95%, subsequent inter-group anlysis conducted using a modified unpaired, twotailed t-test using within group mean square variance. Bonferroni correction was used throughout to allow for multiple group testing [39] ; on this basis, data were considered significant where P 0.05/N, and N = the number of tests performed. For non-parametric data, Kruskal-Wallis followed by Mann-Whitney U testing was performed. Chi-square testing was used to compare proportions between groups (analysis of mRNA species), with Fischer's exact test for small sample sizes.
Results
Mononuclear cell cytokine mRNA Data are expressed as the percentage of samples from each group with detectable mRNA transcripts, and are summarized in Table 2 . In addition, as there was no significant difference in TGF-f2 mRNA detection between mild and moderate IgA nephropathy groups for any of the cytokines tested (P> 0.05), data for these groups have been pooled for statistical analysis. TGF-131 mRNA was detected in 68% (24 of 35) of patients with active, and 70% (7 of 10) inactive IgA nephropathy, but in only 18% (3 of 17) normal (P = 0.0005, and P = 0.005, respectively; chi-square test), and 27% (4 of 15) disease controls (P = 0.28, vs. normal controls). IL-6 transcripts, on the other hand, were detectable in 37% (13 of 35) of patients with active
IgA nephropathy compared with only 6% (1 of 17) normal controls (P = 0.015), but none of the patients in remission, and there was no significant increase in the disease control groups Stratification of samples from both patients and control groups into those with normal range, or increased urinary protein excretion (< or 300 mg124 hr), and serum creatinine levels (< or 120 /LM/liter) failed to demonstrate a significant effect of these variables on the detection of MNC cytokine mRNAs (P 0.1; chi square test; Fig. 5 ). In addition, serum creatinines and urinary protein excretion rates were similar in IgA nephropathy patients with or without detectable IL-6, TNF-a or TGF-f31 transcripts (P> 0.1; Mann-Whitney U test). Finally, there were no significant differences in MNC composition (the percentage of monocytes) between groups to account for these differences in cytokine detection rates (P = 0.24; ANOVA), with an overall mean (SD) of 20.4 (10.9)%.
Class II antigen expression by circulating monocytes The combined mean (SD) percentage of monocytes expressing high levels of DR antigen was 8,8 (4.3)%, with a significant difference between patient and control groups (P = 0.002; ANOVA; Fig. 6 ). This was particularity marked in patients with moderately active IgA nephropathy, 12.6 (4.8)%, compared with normal controls, 6.7 (1.6)% (P < 0.001; t-test), but not in those with mild IgA nephropathy, 8.6 (3.7)%, IgA nephropathy remission, 8.1 (3.6)%, or the disease controls, 7.5 (5.2)% (P > 0.05; compared with normal controls). There was, however, no significant difference between group variation in total DR expression on circulating monocytes (P = 0.35; ANOVA), with combined mean (SD) of 61.2 (21.8)% positive, and no difference in forward light scattering profiles between groups (P =0.42; ANOVA), indicating that these variations in phenotypic expression are not attributable to differences in cell size. Interestingly, DR (high) expression was higher in IgA nephropathy patients 
Discussion
The functional significance of abnormalities in cytokine expression has been investigated in a number of experimental models of glomerulonephritis. Manipulation of mononuclear cell infiltrates [17] [18] [19] and cytokine expression using blocking antibodies [26] [27] [28] or exogenous administration of recombinant cytokines [29] [30] has demonstrated the central importance of both the infiltrating inflammatory cell, and intrarenal expression of cytokines in the modulation of both the acute and chronic glomerular responses to immune injury. Furthermore, studies using the remnant kidney model of progressive glomerular sclerosis demonstrate that infiltrating monocytes [40] and abnormal tissue cytokine expression [41] may also be of importance in controlling excessive scar tissue formation even in the absence of direct immunological injury. In human IgA nephropathy there is also an accumulation of intrarenal inflammatory cell populations [15, 161 and abnormal renal tissue expression of cytokines [31, 32, 421 . Based on the experimental evidence therefore, while the deposition of nephritogenic autoantibodies and other immunoglobins likely to be involved in one limb of the disease process [6, 7] , these findings also suggest an important role for dysregulated tissue cytokine expression and mononuclear cell inifitration in both the initation and perpetuation of renal pathology in this condition.
Abnormal cytokine production by circulating and tissue infiltrating MNCs has also been implicated in the pathogenesis of a number of autoimmune diseases characterized by polyclonal B cell activation and selective tissue damage, including rheumatoid arthritis [43, 44] , and SLE [45] [46] [47] . IgA nephropathy is characterized by polyclonal B cell activation, with elevated levels of circulating IgA 1 [3] associated with polyclonal expansion ofigAl bearing B cells in the bone marrow [4] , in addition to episodic secretion of polymeric IgA [2] , and IgG autoantibodies [6, 7] , but there are limited published data on the pattern of mononuclear cytokine expression in this condition. Furthermore, the study of cytokine expression systems in vivo is complicated by the critical dependance of a tissue response on the balance, or network, of regulatory factors to which the cells are exposed [48] . As a result, the study of isolated cytokines is unlikely to give a realistic picture of pathogenic mechanisms in patients with IgA nephropathy, and for this reason we have simultaneously analyzed a panel of interacting lymphocyte and monocyte derived cytokines in peripheral blood MNC preparations. To do this we have used the PCR technique as a screening procedure to detect multiple cytokine mRNA phenoptypes, as previously described [38] . This has the advantage of being simple to perform, avoiding the requirement for radioisotopic hybridization with Northern blot, or Si nudease analysis, and may be conducted on the small quantities of RNA obtained from fresh MNC preparations. In addition, while the competitive PCR technique may be used to provide an accurate measure of cellular mRNA expression [49] , it involves the generation of mutant cDNA or RNA constructs, and the requirement for multiple RT-PCR reactions to quantify specific mRNA expression, which would be inappropriately complex and time consuming for use as a screening procedure.
Several steps were taken to apply this technique as a semiquantitative analysis. cDNA preparations were performed using known amounts of total RNA, accurately quantified by denaturing gel electrophoresis against an RNA standard. cDNA preparations were subsequently amplified over specified numbers of cycles for each set of primers, with co-amplification of GAPDH mRNA to control for variations in the efficiency of the cDNA synthesis reaction. In addition, we used master mixes of reaction components to minimize variations between individual PCR preparations. In view of the subjective nature of visual assessment of PCR products under ultraviolet light, no attempt was made to quantify the intensity of staining with ethidium bromide, and individual samples were scored as having detectable or undetectable PCR products for a given cytokine mRNA. This approach represents a simplified modification of an established PCR technique [50] , and while it does not provide an absolute measure of mRNA abundance, it does enable a relative A Proteinuria comparison of cytokine transcipt levels between patient and control groups. Finally, specificity of the amplification products was determined by gel electrophoresis, with the detection of rnRNA products of predetermined size, distinct from genomic fragments. While it is possible that these represent non-specific PCR amplification products, it is highly improbable that all of the primers tested should have reproducibly amplified nonspecific products corresponding precisely to the predicted sizes from mRNA sequence data, by chance alone. For this reason, we have avoided the additional complexity of Southern blot hybridization or restriction enzyme digestion experiments to confirm the specificity of our PCR products.
Using this technique, we were able to detect changes in TGF-f31, !L-6 and TNF-a mRNA expression in peripheral hr], and results expressed as the percentage within each new grouping with detectable mRNA species, as shown. There were no significant differences between groups for any of the cytokine transcripts tested (P = 0.1; chi square test).
blood MNCs from patients with IgA nephropathy. This was not associated with a generalized increase in cytokine mRNA expression, as there was no significant alteration in TGF-/32, IL-la, IL-l/3, y-IFN, IL-2 or IL-4 detection. The changes in TGF-f31 and TNF-a mRNA expression appeared to be specific for patients with IgA nephropathy as there were no parallel changes in the disease control group, comprised of eight patients with chronic renal failure of "non-immune" etiology, and seven with mesangial proliferative glomerulonephritis associated with 1gM deposits. Differences in IL-6 mRNA detection were less clear cut. While significantly increased in patients mRNA detection was increased in patients with active IgA nephropathy these changes may not reflect a specific pathogenetic process in this disease. On the other hand, these changes, and the differences in TGF-/31 and TNF-a mRNA expression, were independent of other clinical parameters of renal injury, including serum creatinine and urinary protein excretion rates, evidence that these abnormaiities are, in fact, likely to represent specific immunoregulatory defects in patients with IgA nephropathy. Finally, our empirical stratification of IgA nephropathy disease activity according to urinary red cell excretion rates appears to have been validated as there was a clear distinction in cytokine mRNA detection and monocyte class II antigen expression in those patients with higher grades of urinary blood loss. This corroborates clinical data from Nicholls et al [51] suggesting that urinary erythrocyte excretion is an important prognostic factor in patients with IgA nephropathy. Urinary protein excretion, which has been used as a clinical marker of disease activity in glomerulonephritis, correlates with other clinicopathological indicators of disease chronicity [51, 52] , so that its use as a gauge of acute IgA disease activity may be invalid.
Enhanced expression of TGF-pl mRNA by peripheral blood MNCs has not previously been reported in IgA nephropathy. Unlike the other cytokines, this was up-regulated in all patient groups, irrespective of urinary red cell excretion rates. This suggests that increased expression of TGF-/31 mRNA is unrelated to acute disease activity. Furthermore, these changes in TGF-/31 expression were not associated with an up-regulation in TGF-32 mRNA detection. This is of interest, as this cytokine, while demonstrating marked structural and functional homology to the TGF-J31 isoform, is under separate transciptional control and its expression has been shown to be independantly regulated in different cell types in vitro, and in a number of different settings in vivo [53J. The significance of this differential regulation in TGF-j3 isoforms is, however, unknown.
Given the important role of TGF-$1 in the modulation of glomerular matrix and scar tissue formation [27] , the fact that mesangial expression of the cytokine may be autoinduced [25] , and the potential role of TGF-/3 in IgA switching of B cells [54] , we speculate that these changes in MNC mRNA expression could play a central role in the pathogenesis of IgA nephropathy. However, it is well-recognized that TGF-f3 mRNA expression can be dissociated from active protein secretion [55] , so that these data must be interpreted with caution, and further work is in progress to elucidate the significance of these findings.
IL-6 mRNA was up-regulated in a proportion of patients with active disease. These data confirm our preliminary findings of enhanced spontaneous IL-6 protein secretion by isolated monocytes [12] , and from Ranierei et al using peripheral blood MNC preparations [13] from patients with active IgA disease. The discrepancy with data from Lai et al [11] , who failed to demonstrate any significant increase in IL-6 secretion by cultured MNCs from these patients, probably reflects patient selection and their use of PHA as a mitogen in all the experiments, as this has been shown to mask changes in spontaneous cytokine release by cultured PBMNCs in this condition [13] . Furthermore, their MNC preparations were depleted of monocytes, which are the main cellular source of IL-6 in human peripheral blood [56] , with less than 4% CDI lb positive cells on immunofluorescence analysis, compared with a mean (SD) of 20.4 (10.9)% using CD 14 as a monocyte marker in our study.
IL-6 itself is a highly pleiotropic cytokine with effects on a range of different target cells. Of particular relevance in this context is its central role in the control of B cell differentiation and immunoglobulin secretion [14] , underlying its implicated role in the pathogenesis of rheumatoid arthritis [43, 44] and SLE [45] [46] [47] . Furthermore, it may also have an indirect effect on IgA subclass secretion through selective stimulation of IgA bearing gastrointestinal B cells [57] , which may be of importance in IgA nephropathy. IL-6 is also an autocrine growth factor for cultured mesangial cells [21] , so exogenous secretion of this cytokine by infiltrating glomerular monocytes may rapidly up-regulate endogenous mesangial expression by paracrine . that it may have direct effects on glomerular structure and function in disease states [30] . Down-regulated TNF-a mRNA expression in patients with IgA nephropathy is more difficult to explain. TNF-a mRNA is rapidly up-regulated following ex vivo manipulation of monocytes [36] , so that it was not unexpected to detect PCR products for this cytokine in a 29% of normal, and 53% of disease controls. However, only 7% of patients with IgA nephropathy had detectable TNF-a transcipts. The pathological significance for this is uncertain, but there are parallels for this in patients with SLE nephritis in whom freshly isolated PBMCs have been shown to have a diminished capacity to express TNF-a [45] , and in the (NZB*NZW) ft murine model of SLE nephritis in which there is also down-regulation of TNF-a expression, glomerular injury may be abrogated by the systemic infusion of the recombinant cytokine [58] . In our patients, these changes in TNF-a mRNA may result from an inhibition of cytokine transciption during cell separation by MNC derived IL-6, since exogenous IL-6 has been shown to suppress TNF-a expression by monocytes [59] . Alternatively, there may be "desensitization" of TNF-a expression following repeated exposure to an unidentified exogenous stimulus in patients with IgA nephropathy, a process which has been described following continuous in vitro stimulation of monocytes with lipopolysaccharide [60] .
We were also able to demonstrate an association between yIFN and IL-6 transcript detection in some patients with IgA nephropathy, suggesting an interaction between a T-cell, y-IFN, and a predominantly monocyte derived cytokine, IL-6 [56] , in these patients. Indeed, there is in vitro evidence that exogenous y-IFN may enhance monocyte IL-6 expression [35] , and in patients with IgA nephropathy, PBMNCs have been shown to secrete increased amounts of y-IFN into culture supernatants following mitogen stimulation [11] . Our failure to detect changes in other T cell-derived cytokines, however, conflicts with previously published data suggesting that there is up-regulation of IL-2 expression by PBMNCs from patients with IgA nephropathy [10, 111 . This discrepancy may reflect differences in disease activities between studies, particularly the former in which there is no description of the patients' serum creatinine, urinary protein, or urinary red cell excretion rates [10] . In the latter paper, MNC preparations were highly enriched for lymphocytes [11] , so that our failure to detect significant changes in T cell-derived cytokine mRNAs may simply reflect the lower numbers of lymphocytes in our preparations.
Finally, there was an up-regulation of class II antigen expression on circulating monocytes, confirming data from Rocatello et at [61] , and suggesting an association between monocyte activation and the generation of abnormal cytokine mRNA phenotypes in these patients. The pattern of class II expression, with increased percentages of monocytes with high levels of DR antigen rather than a change in the total numbers of DR positive cells, parallels changes decribed in vitro following stimulation with y-IF'N [62] . Our data also demonstrate an association between high DR expression on circulating monocytes, and the detection of MNC y-IFN, providing further evidence that that this T cell-derived cytokine may be involved in the generation of activation phenotypes in patients with IgA nephropathy. Having said that, the significance of these findings in patients with active IgA nephropathy is uncertain, given the heterogeneity of monocyte DR antigen expression in the different patient and control groups. However, like the IL-6 mRNA expression data, it suggests that within the group of patients with moderately active nephropathy, there are some who may well have a biologically significant increase in DR expression. In a cross sectional study, this is compatible with a transient up-regulation of surface antigen expression on circulating monocytes, which may only be increased in a proportion of the patients at any one time point.
In conclusion, we have demonstrated increased expression of MNC cytokine mRNAs in patients with IgA nephropathy using the PCR technique to analyze multiple mRNA phenotypes.
There was an up-regulation in TGF-J3l and IL-6 mRNA, independent and dependent, respectively, on disease state with down-regulated TNF-a detection, and these were associated with enhanced class II antigen expression on circulating monocytes. Together these data suggest a selective activation of circulating MNCs which could account at least in part, through the secretion of relevant cytokines in lymphatic and renal tissue infiltrates, for the immune system and renal tissue abnormalities seen in patients with IgA nephropathy.
